How Can Data Improve Patient Care?

Any clinical decision where tradeoffs exist is eligible for quantitative modeling, so we fuse the state-of-the-art in quantitative decision science with clinical expertise to inform three research objectives across rare diseases.

The Goshua Lab is the first research program in the United States working at the interface of quantitative decision science and clinical medicine with a focus on rare hematologic and oncologic diseases.

Research Overview

Recognitions

14 orals since 2020 at the premier conferences
11 ASH Orals, 2 SMDM Orals
1 Late-Breaking Oral (European Hematology Association Congress)
#1 Conference Oral (Society for Medical Decision Making)
11 ASH Abstract Achievement Awardees
2 ASH Press Program Selections (<10 selections from >5000 entries)
4 Best of ASH selections (HTRS)
2 Highlights of ASH for North America selections (ASH)
2021 American Journal of Hematology Paper of the Year (YIA)
2022 American Journal of Hematology Paper of the Year finalist (YIA)
#1 cited original research manuscript in The Lancet Haematology
#1 trending manuscript globally on PubMed (Blood)
2021 top 10 Blood Advances manuscript

Collaborators

Harvard School of Public Health
Boston Medical Center
University of Pennsylvania
Emory University
Massachusetts General Hospital
University of York
University of British Columbia
Dana-Farber Data Science
Beth Israel Deaconess Medical Center
Oregon Health & Science University
Memorial Sloan Kettering Cancer Center

Our Research

As in 2017, in 2021 the United States again ranked #11/11 both on overall performance and across several domains of health care system performance in The Commonwealth Fund's reports "Mirror, Mirror 2017"and "Mirror, Mirror 2021". These rankings are despite the known, decades-long breakaway #1 global ranking in healthcare spending as percentage of GDP. Our consistent #11/11 rankings in the domains of Access (i.e., affordability and timeliness), Equity (i.e., difference between low- and high-income individuals), and Healthcare Outcomes (i.e., population health, mortality amenable to health care, disease-specific health outcomes) are in need of informed population- and individual-level clinical decision making via resource allocation optimization. That is, delivering affordable and equitable care at the right time to the right individuals. Quantitative decision science allows an explicit quantification of effect estimates, precision intervals and uncertainty present in any given medical decision where tradeoffs are present. The United States' clinical hematologic-oncologic space is particularly rife with new, expensive therapeutic offerings, many times with unclear effect on quality-of-life, and this is where our laboratory fuses methodologic and clinical expertise.

Ongoing and planned work includes research in alloimmunization, gene therapy, maternal-fetal hematology, complement inhibition, iron deficiency, iron chelation, thrombosis, sickle cell disease, immune-mediated cytopenias, hemophilia, von Willebrand Disease, hereditary hemorrhagic telangiectasia, paroxysmal nocturnal hemoglobinuria, perioperative hematology, with an additional overarching focus on the quantitative capture of health equity considerations where possible in the United States’ context.